The Cancer Center (CORE) Support Grant (CCSG), will provide the necessary financial support that will assure quality administration of major programs in interdisciplinary basic and clinical cancer research, cancer education and training, cancer diagnosis and therapy, and community outreach. It is the intent of the Ohio State University Comprehensive Cancer Center to translate its own and other laboratories' observations into applicable clinical usage and to communicate existing and newly developed therapies, diagnostic procedure and prevention methods to the Ohio Valley Region. The CCSG will provide salary support for directors of vital programs and for key investigators necessary for further Center development. These individuals will collectively help to: Optimally utilize and integrate the cancer center efforts extent within the ten colleges at The Ohio State University engaged in cancer research; (2) Develop new programs, pilot studies and demonstration projects in cancer research, education, diagnosis and therapy within the CCC and at the community levels; (3) Encourage, aid, support and integrate community-run programs which are aimed to meet the need of the respective areas; (4) Develop interdisciplinary activities between clinical and basic scientists to affect the translation process from laboratory to clinical application; (5) Communicate approved new developments on cancer diagnosis, therapy and rehabilitation to cooperating institutions throughout the Ohio Valley Region; (6) Establish effective cooperation with other existing and developing cancer centers including the National Cancer Institute. The Ohio State University Comprehensive Cancer Center will undergo significant development during the coming years that will culminate in broadened interdisciplinary cancer research and cancer control programs. The Opening of the new Arthur G. James Cancer Hospital and Research Institute in 1989 will provide significant new resources to meet the needs of the 1990's and the twenty-first century as part of the nationwide effort to ultimately control cancer totally.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-20
Application #
2086419
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1977-07-01
Project End
1995-06-30
Budget Start
1994-08-29
Budget End
1995-06-30
Support Year
20
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Dietrich, Sascha; Ole?, Ma?gorzata; Lu, Junyan et al. (2018) Drug-perturbation-based stratification of blood cancer. J Clin Invest 128:427-445
Chen, Zhong; Wu, Dayong; Thomas-Ahner, Jennifer M et al. (2018) Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc Natl Acad Sci U S A 115:6810-6815
Moshiri, Farzaneh; Salvi, Alessandro; Gramantieri, Laura et al. (2018) Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget 9:15350-15364
Petrov, Brawnie; Aldoori, Ayat; James, Cindy et al. (2018) Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein. Transl Psychiatry 8:61
Senaras, Caglar; Niazi, Muhammad Khalid Khan; Sahiner, Berkman et al. (2018) Optimized generation of high-resolution phantom images using cGAN: Application to quantification of Ki67 breast cancer images. PLoS One 13:e0196846
Kovac, Rachel L; Ballash, Gregory; Fenger, Joelle et al. (2018) Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib. J Vet Intern Med 32:2061-2068
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Neff, Robert; Rush, Craig M; Smith, Blair et al. (2018) Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers. Int J Cancer 143:2955-2961
Comiskey Jr, D F; Jacob, A G; Sanford, B L et al. (2018) A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo. Oncogene 37:95-106
Bickell, Nina A; Lin, Jenny J; Abramson, Sarah R et al. (2018) Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. J Oncol Pract 14:e23-e33

Showing the most recent 10 out of 2602 publications